“GEMIFATSIAL SPAZMDA KLINIK-FUNKSIONAL MEZONLAR ASOSIDA PERSONALLASHTIRILGAN DAVOLASH ALGORITMINI ISHLAB CHIQISH” (ADABIYOTLAR SHARHI)
##article.subject##:
gemifatsial spazm, botulinotoksin, personallashtirilgan davolash, klinik-funksional mezonlar, in’ektsiya texnikasi, prognoz, hayot sifati, EMG, LSR##article.abstract##
Gemifatsial spazm (GFS) — yuz nervi innervatsiya qiladigan mimik mushaklarning bir tomonlama, ixtiyorsiz qisqarishi bilan kechadigan kranial harakat buzilishi bo‘lib, bemorlarning hayot sifatini sezilarli pasaytiradi. A tipidagi botulinotoksin (BoNT-A) hozirda GFSni simptomatik davolashning birinchi tanlov usuli bo‘lib, bemorlarning 85–95% ida sezilarli yengillik beradi. Biroq davolash samaradorligi, ta’sir davomiyligi va nojo‘ya ta’sirlar har bir bemorda turlicha bo‘lib, yagona standartlashtirilgan protokol mavjud emas. Ushbu sharhning maqsadi — GFSni BoNT-A bilan davolashda samaradorlikka ta’sir etuvchi klinik-funksional mezonlarni tahlil qilish va personallashtirilgan davolash yondashuvining ilmiy asoslarini umumlashtirishdir. Tahlil shuni ko‘rsatadiki, davolashni bemorning klinik-funksional xususiyatlariga moslab individuallashtirish samaradorlikni oshirishi, nojo‘ya ta’sirlar va xarajatlarni kamaytirishi mumkin; bu yo‘nalishda dalilga asoslangan davolash algoritmini ishlab chiqish dolzarb vazifa bo‘lib qolmoqda.
Библиографические ссылки
Rosenstengel C., Matthes M., Baldauf J., Fleck S., Schroeder H. Hemifacial spasm: conservative and surgical treatment options // Dtsch Arztebl Int. — 2012. — Vol. 109(41). — P. 667–673.
Auger R.G., Whisnant J.P. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984 // Arch Neurol. — 1990. — Vol.47(11). — P. 1233–1234.
Yaltho T.C., Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms // Mov Disord. — 2011. — Vol. 26(9). — P. 1582–1592.
Nurminen P., Marjamaa J., Niemelä M., Sairanen T. Incidence and prevalence of hemifacial spasm in Finland’s largest hospital district // J Neurol Sci. — 2023. — Vol. 446. — Art. 120587.
Chaudhry N., Srivastava A., Joshi L. Hemifacial spasm: the past, present and future // J Neurol Sci. — 2015. — Vol. 356(1–2). — P. 27–31.
Anandan C., Jankovic J. Botulinum toxin in movement disorders: an update // Toxins (Basel). — 2021. — Vol. 13(1). — Art. 42.
Wang B., Wei X., Qi H., Bao X., Hu M., Ma J. Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: a systematic review and meta-analysis // BMC Neurol. — 2024. — Vol. 24. — Art. 420.
Tian S., Zheng H., Wu L., Wu W. Factors influencing short-term prognosis after botulinum toxin type A treatment for hemifacial spasm: a retrospective study // Heliyon. — 2024. — Vol. 10(2). — Art. e24898.
Maytharakcheep S., Bhidayasiri R. Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes // J Neural Transm. — 2024. — Vol. 131. — P. 1325–1340.
Traylor K.S., Sekula R.F., Eubanks K., Muthiah N., Chang Y.F., Hughes M.A. Prevalence and severity of neurovascular compression in hemifacial spasm patients // Brain. — 2021. — Vol. 144(5). — P. 1482–1487.
Tighe A.P., Schiavo G. Botulinum neurotoxins: mechanism of action // Toxicon. — 2013. — Vol. 67. — P. 87–93.
Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action // Arq Neuropsiquiatr. — 2005. — Vol. 63(1). — P. 180–185.
Tugend M., Ulane C.M., Patel K., Sekula R.F. Jr. Decompression surgery in elderly patients with hemifacial spasm refractory to botulinum toxin // Mov Disord Clin Pract. — 2024. — Vol. 11(8). — P. 966–972.
Hallett M., Albanese A., Dressler D., et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders // Toxicon. — 2013. — Vol. 67. — P. 94–114.
Eiamsamarng A., Chirapapaisan N., Chuenkongkaew W., et al. Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial // Ann Med. — 2025. — Vol.57(1). — Art. 2537921.
Teekaput C., Teekaput K., Thiankhaw K. Preseptal and pretarsal botulinum toxin injection in hemifacial spasm and blepharospasm: a 10-year comparative study // Ther Clin Risk Manag. — 2023. — Vol. 19. — P. 35–42.
Çakmur R., Ozturk V., Uzunel F., Donmez B., Idiman F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm // J Neurol. — 2002. — Vol. 249(1). — P. 64–68.
Boussetta K., Hajjij A., Regragui W., Anajar S., Degos B., Majer J., Asly M. Multicentric comparative study of botulinum toxin treatment in patients with hemifacial spasm // Eur Arch Otorhinolaryngol. — 2025. — DOI: 10.1007/s00405-025-09425-6.
Al Menabbawy A., Ruhser L., El Refaee E., Weidemeier M.E., Matthes M., Schroeder H.W.S. From spasms to smiles: how facial recognition and tracking can quantify hemifacial spasm severity and predict treatment outcomes // Acta Neurochir (Wien). — 2025. — Vol. 167. — Art. 4.
Møller A.R., Jannetta P.J. Microvascular decompression in hemifacial spasm: intraoperative electrophysiological observations // Neurosurgery. — 1985. — Vol. 16(5). — P. 612–618.
Thirumala P.D., Altibi A.M., Chang R., Saca E.E., Iyengar P., Reddy R., Anetakis K., Crammond D.J., Balzer J.R., Sekula R.F. The utility of intraoperative lateral spread recording in microvascular decompression for hemifacial spasm: a systematic review and meta-analysis // Neurosurgery. — 2020. — Vol. 87(4). — P. E473–E484.
Sarı Ü.S., Eroglu M., Büyükşerbetçi G., Tokucoglu F., Sahin N. Positive effect of self-exercise following botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: a clinical trial // Medicine (Baltimore). — 2024. — Vol. 103(24). — Art. e38215.
